試す 金 - 無料
Demand For Specialised Infrastructure, Incubators Continues To Be Moderate To Strong
Bio Spectrum
|February 2017
Utkarsh Palnitkar says only a few biotech parks support industry with ready-to-use lab facilities for R&D, incubation support for start-ups and dedicated land for scaling up activities are operational in India.
Admitting that there is a sustained interest across the biopharma value chain, Utkarsh Palnitkar, Co-Chairman of the Review Committee for Biotech Parks, DBT, Government of India (GoI), Partner and National Head (Infrastructure, Government, Healthcare and Life Sciences Practice), KPMG, states that the demand for specialised infrastructure and incubators continues to be moderate to strong. He tells BioSpectrum that more than 15 biotech parks are operating currently in the country and many upcoming parks are still at an initial stage of conducting basic ground work for their establishment.
What is the current status of BT parks in India and their occupancy level? Which states are doing great, which are ok and which are below average? Some parks believed to have very low level of occupancy. Which are they and what are the reasons for the same?
With the sustained interest across the biopharma value chain, the demand for specialised infrastructure and incubators continues to be moderate to strong. Currently, more than 15 biotech parks are operational in the country and many upcoming parks are still at an initial stage of conducting basic ground work for their establishment.
The Department of Biotechnology (DBT), together with various state governments are playing a major role in setting up biotechnology parks across the country.
The occupancy level in biotech parks depends upon various factors such as the availability of the specialised infrastructure, incubation facilities, enabling ecosystem and state policies, among others. The prevalence of a vibrant ecosystem is essential to the success of the Park. While at many locations elements of the ecosystem exists, they being joined together is at time absent. This is reflected in the mixed level of success in this space.
このストーリーは、Bio Spectrum の February 2017 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー
Bio Spectrum
Can India's CDMOS Lead the Next Biopharma Wave?
India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).
8 mins
March 2026
Bio Spectrum
Telangana turns catalyst for innovation
Telangana is at a pivotal moment in its journey as a global life sciences hub.
6 mins
March 2026
Bio Spectrum
Is AI the New Weapon in the Fight to End TB?
A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).
2 mins
March 2026
Bio Spectrum
ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India
US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.
1 min
March 2026
Bio Spectrum
Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy
Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.
5 mins
March 2026
Bio Spectrum
"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"
Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.
5 mins
March 2026
Bio Spectrum
Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer
Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.
1 min
March 2026
Bio Spectrum
Haleon ropes in Kedar Lele as President for India Subcontinent
Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.
1 min
March 2026
Bio Spectrum
Centre revises Startup Recognition Framework to strengthen Startup India Action Plan
The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.
1 min
March 2026
Bio Spectrum
"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"
In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.
5 mins
March 2026
Translate
Change font size

